Skip to main content

Industry News

  • Wockhardt has received final approval from the US FDA for marketing 5mg/5ml of oxycodone HCI liquid. The company is launching the product soon and will be amongst the few generic versions of this product in the market.

  • Aurobindo Pharma got final approvals from the US FDA of azithromycin for injection USP, 500mg /vial and entacapone tablets. Azithromycin for injection USP, 500mg/vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (azithromycin for injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as community-acquired pneumonia and pelvic inflammatory disease.

  • Shri B P Sharma, Secretary Health, Ministry of Health & Family Welfare and Chairman, Indian Pharmacopoeia Commission, Government of India launched an Android Mobile Applications for Adverse Drug Reactions (ADRs) reporting facility to the stakeholders of Pharmacovigilance Programme of India (PvPI). The mobile application for ADR reporting was specifically designed to facilitate the needs of the IPC, to ensure hassle free ADR reporting for the stakeholders. The mobile application is expected to provide a platform for the private healthcare professionals to report ADRs to safeguard and enhance public health by ensuring the safety, efficacy and quality of drugs.

  • (NewsVoir); Aggressively moving towards its expansion plans, 1mg.com - India’s leading m-health platform that has also been operating the largest e-Pharmacy marketplace in the country, announced today that it has decided to expand the scope of its platform and is entering the alternate medicine space (AYUSH categories) through the acquisition of www. Homeobuy.com. Homeobuy is a web platform for homeopathy medicines. With this acquisition, 1mg will re-brand the website to www. 1mgAyush.com and make Homeopathic & Ayurvedic medicines available to customers in New Delhi.

    [adsense:336x280:8701650588]

  • Sandoz, a Novartis company, has launched Glatopa in US markets. Glatopa is the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. It is used in treatment of Multiple Sclerosis (MS).

  • Intas Pharmaceuticals on Friday announced launching of Razumab, a biosimilar to Lucentis (ranibizumab). Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up.  Razumab will be 25 per cent cheaper than its imported alternate.

  • Lilly, Dana-Farber Cancer Institute collaborate to develop new medicines to treat cancer

    Eli Lilly and Company and Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School,  collaborate  to research new medicines under development  to fight cancer.

  • Daiichi Sankyo Company, Limited's generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients. The products: Naftopidil OD tablets 25mg, 50mg, 75mg “DSEP” (Flivas OD tablets 25mg, 50mg, 75mg) for the treatment for urination disorder due to enlargement of prostate; Metformin hydrochloride tablets 250mgMT, 500mgMT “DSEP” (Metgluco tablets 250mg, 500mg) for biguanide-type oral hypoglycemic agent; Letrozole tablets 2.5mg “DSEP” (Femara tablets 2.5mg)  Aromatase inhibitor/postmenopausal breast cancer treatment; Oxaliplatin IV infusion solution 200mg “DSEP” (Elplat IV infusion solution 200mg) anti-malignant tumour agent.

  • Dr. Reddy’s today announced the launch of HAiROOTZ™, the first hair growth supplement to be marketed in India as over-the-counter (OTC) by the company. HAiROOTZ™ comes from the same branch of business that markets MINTOPTM, the No. 1 dermatologist recommended brand in the country.

  • The US Food and Drug Administration (FDA) has accepted for review Teva Pharmaceutical's Biologics License Application (BLA) for reslizumab for the treatment of inadequately controlled asthma in adult and adolescent patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.

Subscribe to Industry News